Similarly, in experimental autoimmune encephalomyelitis, combination therapy with lovastatin and an AMPK activator improved mitochondrial and peroxisomal function, upregulated MnSOD, and reduced disease severity, positioning MnSOD as a therapeutic effector in metabolically guided treatment of MS [227]. The gene discussed is SOD2; the disease is experimental autoimmune encephalomyelitis.